疟疾治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00018229
  • Category : Pharmaceuticals
  • Status : Published
  • No. of Pages : 320
Buy Now

【研究报告】2022年疟疾治疗市场价值32.9698亿美元,预计到2030年将达到244.8773亿美元;预计 2022 年至 2030 年复合年增长率为 28.5%。
市场洞察和分析师观点:
疟疾是一种由疟原虫寄生虫引起的危及生命的传染病。由于低收入国家疟疾发病率高以及国际和国家组织发起的全球疟疾消除计划,疟疾治疗市场正在不断增长。此外,先进诊断工具的不断推出和提供有效治疗方法的研究活动的增加正在推动疟疾治疗市场的增长。在疫情大流行的两个高峰年(2020 年至 2021 年),与新冠肺炎相关的干扰导致超过 1,300 万例疟疾病例和 63,000 人相关死亡。世卫组织非洲区域在全球疟疾负担中仍然占据着不成比例的巨大份额。 2021 年,约 95% 的疟疾病例和 96% 的死亡病例发生在非洲。此外,5 岁以下儿童约占该地区所有疟疾死亡人数的 80%。据同一来源称,尼日利亚、刚果民主共和国、坦桑尼亚联合共和国和尼日尔占全球疟疾死亡人数的一半以上。
增长动力和挑战:
疟疾,一种急性发热性疾病疾病是由疟原虫引起的,并通过受感染的雌性按蚊传播。人类体内的五种寄生虫主要引起疟疾,其中两种——恶性疟原虫和间日疟原虫——被认为是对人类健康的最大威胁。此外,恶性疟原虫是最致命的疟疾寄生虫,在非洲大陆传播最广泛。此外,间日疟原虫是撒哈拉以南非洲以外大多数国家的主要疟疾寄生虫。根据世界卫生组织 (WHO) 最新发布的《2020 年世界疟疾报告》(WMR),全球报告了 2.41 亿例疟疾病例,而 2019 年记录的病例数为 2.27 亿例。疟疾造成的死亡人数每年增加 69,000 人。其中大约三分之二(即 47,000 人)是由于 COVID-19 爆发期间医疗服务中断造成的;其余三分之一的死亡人数,即 22,000 人,反映了世界卫生组织计算疟疾死亡率的方法最近发生的变化(不考虑 COVID-19 的干扰)。因此,全球不同地区疟疾患病率不断上升,推动了疟疾治疗市场的增长。
抗疟药物耐药性的发生可能是由于假药的供应和使用不断增加、过度使用某些药物进行预防、不完全使用等原因造成的。活动性感染的治疗,以及寄生虫在遗传和代谢水平上的适应性等。假冒抗疟药物的使用增加是全球医疗保健部门面临的主要问题。由于医疗费用高昂,大多数非洲国家普遍使用假冒抗疟药物。人们还选择购买假药来以较低的成本接受治疗,而一些国家缺乏合理的质量控制和验证流程,这使得人们更容易获得这些假药。据《2020 年媒介传播疾病杂志》报道,假冒抗疟药物不仅造成经济损失,而且降低了治疗效果,从而导致人们对医疗保健系统失去信心,并增加了寄生虫产生耐药性的机会.
因此,假冒抗疟药物的崛起阻碍了疟疾治疗市场的增长。
战略见解
报告细分和范围:
根据治疗,疟疾治疗市场细分为仿制药、原研药、疫苗等。根据给药途径,疟疾治疗市场分为口服和肠胃外。根据分销渠道,疟疾治疗市场分为直接招标、医院药房、零售药房、网上药房等。按地理位置划分,疟疾治疗市场分为北美(美国、加拿大和墨西哥)、欧洲(英国、德国、法国、意大利、西班牙和欧洲其他地区)、亚太地区(中国、日本、印度、澳大利亚、韩国和亚太地区其他地区)、中东和非洲(沙特阿拉伯、阿联酋、南非、肯尼亚、坦桑尼亚、卢旺达、尼日利亚、加纳、乌干达、安哥拉、喀麦隆、塞内加尔、赞比亚和其他地区)中东和非洲)以及南美洲和中美洲(巴西、阿根廷以及南美洲和中美洲其他地区)。
细分分析:
按治疗划分的疟疾治疗市场 – 2022 年和 2030 年
基于治疗方面,疟疾治疗市场分为仿制药、原研药、疫苗等。 2022年,疫苗领域占据最大的市场份额。此外,预计该细分市场在预测期内将创下最高复合年增长率。疫苗提供针对特定传染病的主动获得性免疫力。由于研发活动的增加和候选疫苗管道的增加,疟疾疫苗市场正在以显着的速度增长。唯一获得批准的疟疾疫苗是葛兰素史克公司开发的 RTS,S 疫苗,用于防止恶性疟原虫疟疾寄生虫进入肝脏。它需要注射四次,并通过撒哈拉以南非洲国家的国家免疫计划向幼儿提供。该疫苗是作为 2019 年开始的试点引进的一部分提供的。国际和地方合作一直是疫苗开发不可或缺的一部分,到 2024 年试点推出结束时; RTS,S 的资金估计超过 10 亿美元,其中葛兰素史克 (GSK) 将提供 7 亿美元,葛兰素史克已为试点捐赠了 1000 万剂疫苗。
疟疾治疗市场,按给药途径,分为口服和肠胃外。 2022年,口腔细分市场将占据更大的市场份额。然而,预计注射剂领域在预测期内将录得更高的复合年增长率。口服给药是最优选和最合适的给药途径,因为它具有较高的患者依从性、无创性、最少的无菌限制、成本效益、剂型设计的灵活性以及制造过程的简便性。易于给药和长期成本效益等优点是推动口服药物采用的主要因素。片剂、胶囊和其他口服药物的低制造成本也是疟疾治疗市场增长的关键驱动因素。一些可用的抗疟疾药物包括奎宁、奎尼丁、氯喹、阿莫地喹、他非诺喹、氯胍、氯丙胍和青蒿素。 ACT 和联合疗法正用于治疗由恶性疟原虫引起的单纯性疟疾。 ACT是目前市场上最有效的抗疟药物。
按分销渠道,疟疾治疗市场分为直接招标、医院药房、零售药房、网上药房等。 2022年,直接招标领域占据最大市场份额。此外,预计同一细分市场在预测期内也将创下最高复合年增长率。招标是履行特定职责或提供固定金额物品的要约。在此招标程序的第一步中,承包商将被要求提交密封的施工标书或在特定时限内提供特别计划的服务或产品。印度的电子招标程序旨在确保政府或特定客户的工作及时完成。例如,一些地方可能有具体的采购法规,规定了决策方式和接受哪些投标。例如,全印度医学科学研究所、比哈尔邦医疗服务和基础设施有限公司(比哈尔邦政府)、巴特那 (AIIMS 巴特那) 董事总经理邀请知名、经验丰富、财力雄厚的公司/公司/机构投标疟疾检测印度不同医疗机构的试剂盒和药物。
区域分析:
根据地理位置,疟疾治疗市场分为五个主要区域:北美、欧洲、亚太地区、南美洲和中美洲以及中东东非。对北美市场的分析主要集中在三个主要国家——美国、加拿大和墨西哥。 2022 年,中东和非洲在疟疾治疗市场中占据最大份额。可支配收入的增加、对有针对性营养的需求不断增长以及对疟疾治疗和补充剂的认识不断提高是推动市场增长的几个重要因素。
尼日利亚的疟疾治疗市场占有最大的市场份额,沙特阿拉伯是预测期内增长最快的市场。根据严重疟疾观察站的报告,疟疾在尼日利亚全国十分突出,约97%的人口面临着患疟疾的高风险。此外,根据《2021 年世界疟疾报告》,尼日利亚记录的疟疾病例数量最多,死亡人数也最高,即 2020 年,该国记录的疟疾死亡人数约占全球疟疾死亡人数的 32%。疟疾方面,尼日利亚与国家消除疟疾计划 (NMEP) 合作,在世界卫生组织的技术支持下启动了高负担高影响 (HBHI) 方法。
疟疾治疗市场机会:
市场参与者不断增加的战略举措
疟疾治疗市场的一些主要参与者越来越注重采用各种策略,例如产品创新、发布和批准;研发投资;以及并购以保持竞争力。下面提到了其中一些举措:
2022 年 3 月,他非诺喹(一种用于治疗特定疟疾菌株的新药)在澳大利亚获得了 Medicines for Malaria Venture (MMV) 的许可,MMV 与葛兰素史克 (GlaxoSmithKline) 共同开发了该药物。 GSK)适用于儿童和青少年。该药与广泛使用的抗疟药——氯喹联合使用。2021年12月,Zydus Cadila宣布计划与Medicines for Malaria Venture合作开发其抗疟药ZY19489,并获得美国FDA批准。据该公司称,ZY19489的I期试验证明了其半衰期长,并且具有单剂量治愈疟疾的潜力。在一项单独的疟疾挑战试验中,单次口服剂量 ZY19489 后显示出强大的抗疟活性。因此,市场参与者的上述战略举措预计将为未来几年的疟疾治疗市场提供增长机会。
竞争格局和主要公司:
全球疟疾治疗市场的一些知名企业包括 Cipla Ltd、Sun Pharmaceutical Industries Ltd、Sanofi SA、GSK Plc、Novartis AG、Pfizer Inc、Emmaus Life Sciences Inc 、AdvaCare Pharma USA LLC、VLP Therapeutics LLC、Lupin Ltd 和 Teva Pharmaceutical Industries Ltd。这些公司专注于新技术的开发、现有产品的进步以及地理覆盖范围的扩大,以满足全球不断增长的消费者需求并扩展其产品专业组合范围。在全球疟疾治疗市场运营的公司正在实施各种无机和有机战略。其中一些如下:
2022 年 11 月,诺华和 Medicines for Malaria Venture (MMV) 宣布决定进入 3 期研究,研究一种新型非青蒿素组合,用于治疗无并发症的疟疾。这种新颖的组合还含有经过优化的苯芴醇配方,使其可以每天服用一次,而不是通常的每天两次。 2021 年 10 月,葛兰素史克 (GSK) plc 欢迎世界卫生组织关于更广泛部署葛兰素史克 RTS,S 疟疾的建议疫苗,以减少儿童疾病和儿童因疟疾死亡(生活在撒哈拉以南非洲和其他中度至高度传播的地区)。 RTS,S 是第一个也是唯一一个在关键长期临床试验中显示可显着减少儿童疟疾的疟疾疫苗。该疫苗是 GSK 与 PATH 及其他合作伙伴领导的 30 多年研究的成果。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


Who are the key players in the malaria treatment market?

Cipla Ltd, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Sanofi SA., GSK Plc, Novartis AG, Pfizer Inc, AdvaCare Pharma USA LLC, VLP Therapeutics LLC, Lupin Ltd among others are among the leading companies operating in the malaria treatment market.

What is the regional market scenario of the malaria treatment market?

Malaria treatment market is segmented by countries comprising of North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America.

Which treatment segment held the largest market share in the malaria treatment market?

The vaccines segment dominated the malaria treatment market and accounted for the largest market share in 2022.

Which distribution channel segment held the largest market share in the malaria treatment market?

Malaria is a serious infection spread by an infected mosquito. The infection is very common in certain parts of the world, such as large areas of Africa and Asia, Central and South America, and the Dominican Republic and Haiti. However, malaria is an entirely preventable and treatable disease if tackled at an early stage. For example, malaria is treated with a prescription drug to kill the parasite. The types of drugs and the length of treatment vary depending on the type of malarial parasite infection, the severity of symptoms, and age.

What are the driving factors for the malaria treatment market across the globe?

increasing prevalence of malaria and government and private sector's initiative to raise awareness about malaria are the most significant factors responsible for the overall market growth.

Which distribution channel segment held the largest market share in the malaria treatment market?

The direct tender segment dominated the malaria treatment market and accounted for the largest market share in 2022.

Which route of administration segment led the malaria treatment market?

Based on route of administration, the oral segment took the forefront leaders in the worldwide market by accounting largest share in 2022 and is expected to continue to do so till the forecast period.

What is meant by the malaria treatment market?

Malaria is a serious infection spread by an infected mosquito. The infection is very common in certain parts of the world, such as large areas of Africa and Asia, Central and South America, and the Dominican Republic and Haiti. However, malaria is an entirely preventable and treatable disease if tackled at an early stage. For example, malaria is treated with a prescription drug to kill the parasite. The types of drugs and the length of treatment vary depending on the type of malarial parasite infection, the severity of symptoms, and age.

The List of Companies - Malaria Treatment Market

  1. Cipla Ltd
  2. Pfizer Inc
  3. Sun Pharmaceutical Industries Ltd
  4. Sanofi SA.
  5. GSK Plc
  6. Novartis AG
  7. Pfizer Inc
  8. AdvaCare Pharma USA LLC
  9. VLP Therapeutics LLC
  10. Lupin Ltd

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports